Status and phase
Conditions
Treatments
About
The primary purpose of this study is to characterize the safety profile of BMS-986408 as monotherapy and in combination with nivolumab or nivolumab and ipilimumab to establish the maximum tolerated dose (MTD). The Recommended Phase 2 Dose (RP2D) that optimizes the pharmacokinetic/pharmacodynamic (PK/PD) relationship of BMS-986408 will also be determined.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Other protocol-defined inclusion/exclusion criteria apply
Primary purpose
Allocation
Interventional model
Masking
101 participants in 7 patient groups
Loading...
Central trial contact
First line of the email MUST contain NCT # and Site #.; BMS Study Connect Contact Center http://www.bmsstudyconnect.com
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal